Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04776239
Other study ID # 20200874
Secondary ID 1R01HL134558-01
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 16, 2021
Est. completion date July 16, 2024

Study information

Verified date September 2023
Source University of Miami
Contact Carlos E Alfonso, MD
Phone (305) 2437589
Email calfonso@med.miami.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 16, 2024
Est. primary completion date July 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Be = 18 years of age (males and females). 2. Provide written informed consent. 3. Have a diagnosis of symptomatic ischemic heart disease (IHD) and an indication for standard-of-care coronary angiography. 4. Have Diabetes Mellitus (DM) type 2 documented by glycated hemoglobin (HbA1C) > 7%, or on medical therapy for diabetes. Exclusion Criteria: 1. Be younger than 18 years of age. 2. Have history of prior myocardial Infarction and revascularization. 3. Have a baseline glomerular filtration rate (GFR) <30 ml/min 1.73m2 estimated using the Modification of Diet for Renal Disease (MDRD) formula. 4. Have poorly controlled blood glucose levels with hemoglobin A1C > 8.5% in the previous 3 months. 5. Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment. 6. Have an indication for standard-of-care surgical (including valve surgery, placement of left-ventricular assist device) or percutaneous intervention for the treatment of valvular heart disease (including valvuloplasty). 7. Have known hypersensitivity or contraindication to aspirin; both heparin and bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor); or any zotarolimus, cobalt, chromium, nickel, tungsten, acrylic, or fluoropolymers; or hypersensitivity to contrast media that cannot be adequately premedicated. 8. Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/microliter (uL) or platelet values < 100,000/uL without another explanation (per investigator discretion). 9. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal. 10. Have a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions. 11. Be an organ transplant recipient or have a history of organ or cell transplant rejection. 12. Have a clinical history of malignancy within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively-treated basal cell or squamous cell carcinoma, or cervical carcinoma. 13. Have a condition that limits lifespan to < 1 year. 14. Have a history of drug or alcohol abuse within the past 24 months. 15. Be serum positive for HIV, hepatitis B surface antigen (sAg), or viremic hepatitis C. 16. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. 17. Be pregnant, nursing, or of childbearing potential and not on contraceptive medications. (May participate if on 2 forms of contraceptives). 18. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up. 19. Coronary lesions with restenosis or heavy calcification.

Study Design


Intervention

Drug:
100 million Allogeneic Mesenchymal Human Stem Cells
1 single intravenous infusion
Other:
Placebo
Placebo delivered via peripheral intravenous infusion

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Miami National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR Coronary Flow Reserve (CFR) as measured via cardiac catheterization angiography 6 months (post-infusion)
Primary Post-PCI coronary artery endothelial function as assessed via FFR Fractional Flow Reserve (FFR) as measured via cardiac catheterization angiography 6 months (post infusion)
Secondary Target lesion lumen loss Target lesion lumen loss as assessed by quantitative coronary angiography (QCA). 6 months (post-infusion)
Secondary Flow Mediated Diameter Percentage (FMD%) FMD% is measured via brachial artery ultrasound 6 months post-infusion
Secondary EPC-CFUs levels Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples. 6 months post-infusion
Secondary Circulating angiogenic factors marker levels Circulating angiogenic marker levels including Protein Kinase B, Stromal Cell Derived Factor 1 (SDF-1), Notch, Vascular Endothelial Growth Factor (VEGF) and Colony Forming Units (CFU) will be assessed from blood samples. 6 months post-infusion
Secondary Circulating inflammatory markers Circulating inflammatory markers including Cluster of Differentiation (CD) 3 CD 25 or CD 3 CD 69 will be assessed from blood samples. 6 months post-infusion
Secondary Seattle Angina Questionnaire (SAQ) Angina Frequency SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. 6 months post-infusion
Secondary EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire EQ-5D Quality of Life Questionnaire has a total score ranging from 0-10 with higher scores indicating better quality of life. 6 months post-infusion
Secondary EQ-5D Quality of life Questionnaire Overall Health Status Question EQ-5D Quality of Life Questionnaire Overall Health Status question has a total score ranging from 0-100 with higher scores indicating better quality of life. 6 months post-infusion
Secondary Short Form (SF) 36 Questionnaire Quality of Life Questionnaire SF 36 Quality of Life Questionnaire consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. Lower scores indicate the more disability, and higher scores indicate less disability. 6 months post-infusion
Secondary International Index of Erectile Function (IIEF) Questionnaire IIEF is a 15 item questionnaire to be completed by males only, with scores ranging from 0-75. Higher scores indicate better male sexual function/quality of life. 6 months post-infusion
Secondary Sexual Quality of Life - Females (SQOL-F) Questionnaire SQOL-F Questionnaire is an 18 item questionnaire in which female participants are asked to record responses on a 6-point Likert scale (completely agree to completely disagree). Total score can range from 18 to 108. Higher scores indicate better female sexual quality of life. 6 months post-infusion
Secondary Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE) TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias or atrial fibrillation. TE-SAEs will be assessed by treating physician. 1 month post infusion
Secondary Incidence of Major Adverse Cardiac Events (MACE) Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal MI. MACE will be assessed by treating physician. 12 months
Secondary Rates of Adverse Events Rates of treatment emergent adverse event (AE) and serious adverse event (SAE) as assessed by treating physician will be reported. 12 months
Secondary Number of participants with abnormal lab values Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician. 12 months
Secondary Number of participants with Target Vessel Failure Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI 12 months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A